Gustaaf W. van Imhoff

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma

Michael Schaapveld, Berthe M.P. Aleman, Anna M. van Eggermond et al. · New England Journal of Medicine · 2015 · 626 citations · Full text

Medicine, Oncology, Cancer Control +13

Rituximab treatment in patients with primary Sjögren's syndrome: An open‐label phase II study

Justin Pijpe, Gustaaf W. van Imhoff, Fred K. L. Spijkervet et al. · Arthritis & Rheumatism · 2005 · 495 citations

Life Sciences, Clinical Sciences, Immunology +15

Comparison of CHOP Chemotherapy with Autologous Bone Marrow Transplantation for Slowly Responding Patients with Aggressive Non-Hodgkin's Lymphoma

Leo F. Verdonck, Wim L.J. van Putten, Anton Hagenbeek et al. · New England Journal of Medicine · 1995 · 280 citations · Full text

Medicine, Hematology, Oncology +17

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

Gustaaf W. van Imhoff, Andrew McMillan, Matthew J. Matasar et al. · Journal of Clinical Oncology · 2017 · 237 citations · Full text

Medicine, Immunology, Oncology +14

Prognostic Impact of Germinal Center–Associated Proteins and Chromosomal Breakpoints in Poor-Risk Diffuse Large B-Cell Lymphoma

Gustaaf W. van Imhoff, Evert-Jan G. Boerma, Bronno van der Holt et al. · Journal of Clinical Oncology · 2006 · 173 citations

Medicine, Hematology, Oncology +17